Quintrio
Home

INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL

Senseonics Holdings, Inc. Common Stock

SENS

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Last trade $10.73
Day change -$0.17 (-1.56%)
Day range $10.48 – $11.82
Volume 1,379,403
Market cap $597M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$597.11M
Price / earnings
—
Price / book
7.69×
Price / sales
9.95×
EV / sales
10.09×
EV / EBITDA
-5.1×

Profitability

Earnings per share
-$2.24
Return on assets
-75.4%
Return on equity
-157.87%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.72×
Current ratio
5.92×
Quick ratio
5.6×
Cash ratio
1.85×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$114.02M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SENS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$19.56M$14.48M$11.71M$14.26M$8.1M$6.65M$6.26M$8.3M
Cost of revenue$7.49M$5.92M$4.77M$6.59M$4.63M$3.53M$4.75M$4.35M
Gross profit$12.07M$8.56M$6.94M$7.67M$3.47M$3.12M$1.51M$3.95M
Selling, general and administrative$32.26M$32.91M$30.18M$19.78M$15.31M$9.73M$7.69M$8.86M
Research and development$11.67M$11.64M$8.61M$8.82M$7.76M$7.72M$7.3M$9.36M
Total operating expenses$43.93M$44.55M$38.79M$28.59M$23.07M$17.44M$14.99M$18.22M
Operating income-$31.86M-$35.99M-$31.85M-$20.93M-$19.6M-$14.32M-$13.49M-$14.27M
Interest expense-$1.81M-$1.6M-$1.19M-$1.21M-$1.17M-$1.15M-$1.43M-$2.17M
Income before taxes-$32.68M-$36.71M-$32.33M-$20.82M-$19.53M-$14.5M-$14.26M-$15.48M
Income taxes$0$0$0$0$0$0$0$0
Net income-$32.68M-$36.71M-$32.33M-$20.82M-$19.53M-$14.5M-$14.26M-$15.48M
Net income attributable to common shareholders-$32.68M-$36.71M-$32.33M-$20.82M-$19.53M-$14.5M-$14.26M-$15.48M
EBITDA-$31.38M-$35.44M-$31.3M-$20.54M-$19.23M-$13.95M-$13.1M-$13.51M
Basic earnings per share-$0.50-$0.63-$0.71-$0.46-$0.43-$0.36-$0.40-$0.46
Diluted earnings per share-$0.50-$0.63-$0.71-$0.46-$0.43-$0.36-$0.40-$0.46

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates

Senseonics Holdings (SENS) reported a quarterly loss of $0.5 per share, slightly missing consensus estimates of $0.49, though revenues of $19.56 million exceeded expectations by 19.06%. The company has outperformed the S&P 500 by 55.6% year-to-date but maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions. MDxHealth SA is expected to report results on November 12 with anticipated quarterly losses.

GlobeNewswire Inc.

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component

Senseonics announced the initiation of its first-in-human clinical study for Freedom, an investigational next-generation continuous glucose monitoring (CGM) system designed to communicate directly with mobile devices without an external transmitter. Built on proven Eversense 365 technology and supported by encouraging preclinical data, Freedom aims for potential commercial launch in 2028, with a pivotal study expected to begin in 2027.

Zacks Investment Research

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

Beta Bionics announced a partnership with Senseonics to integrate the Eversense 365 continuous glucose monitor with its iLet and future mint AID systems. The integration, launching in Q4 2026, will make iLet compatible with more CGM manufacturers than any other AID system. Despite the strategic partnership, BBNX shares fell over 8% following the announcement.

GlobeNewswire Inc.

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 20, 20251-for-20reverse split